

28 DIVISION PSYCHOPHARMACOLOGY AND SUBSTANCE ABUSE

From the President's Desk

Ryan Vandrey, Ph.D.,

Greetings Division 28!

It is with great honor and humility that I begin my term as Division 28 President. The [list of past presidents of the division](#) shows an incredible lineage of scientific superheroes, men and women who pioneered and pushed the boundaries for the discipline we call psychopharmacology. Each were exemplary leaders for APA and Division 28, and I have greatly admired and learned from them all, either through direct mentoring or through reading their scientific accomplishments. To be included among their ranks is pretty humbling (and downright awesome).

One of the people I most admire from that list is our current past-president, Kelly Dunn. Kelly helped navigate the division through the challenges brought on by the COVID pandemic. Not only did Kelly keep the division afloat, but she greatly strengthened its foundation and charted a very clear path for its future. Through a series of meetings with executive committee members, she developed a 5-year plan for the division focused on building membership, creating mentoring and training opportunities, improving diversity, equity and inclusion, expanding our social media presence, engagement in advocacy, and expanding relations with other APA divisions. I am thankful for her vision and leadership and will do my best to keep the division on track with these new initiatives. Kelly, thank you for your outstanding service!



Though this is my first newsletter column as president, know that the executive committee and I have already been hard at work behind the scenes this year to support the division. One of our primary tasks was to put together programming for the first face-to-face convention since 2019. Jake Borodovsky has done a fantastic job as program chair for Division 28 as we prepare for a stellar slate of events at the annual APA convention to be held Aug 4-6 in Minneapolis, MN. See his column for details on events that Division 28 is sponsoring. It will be great to see everyone in person again!

Another exciting development has been an expansion of our social media efforts. Andrea Vásquez Ferreiro is chairing the social media committee, and the executive committee unanimously approved allocating funds, which will allow Andrea and other social media committee members to significantly advance the presence of Div. 28 on platforms such as Twitter and Facebook. Please tag Division 28 on your science-related posts, share new publications, and post pics from the convention this year. Also, look for new content from the division as well, including spotlights on new members. If you are savvy with social media and are interested in helping with this initiative, please reach out to Andrea (avasquezferreiro@ufl.edu) or myself (rvandrey@jhmi.edu).

President-elect Tom Gould and I also met with Vanessa Hintz at the APA Office of Equity, Diversity and Inclusion last month to discuss the rollout of EDI initiatives that APA is undertaking and discussion of how Division 28 can both set an example for other divisions and assist APA in these

important areas. As you may recall from Kelly's last newsletter column, Divisions 28 and 50 received a CODAPAR interdivisional grant to develop a structured mentoring program for promoting under-represented minorities in psychology. Work on this program is underway with Bill Stoops, Neo Gebru, Mariel Bello, and Justin Strickland running point for Division 28. Hopefully lots more to come on that and other EDI initiatives throughout the rest of the year.

I also want to take a moment to thank all the members of the Div. 28 executive committee. Their dedication to the division and the continuity we have has allowed for a pretty seamless transition on my end. That being said, there are several members who are slated to rotate off the executive committee at the end of this calendar year. Those include Matt Kirkpatrick (secretary), Will Aklin (treasurer), Meredith Berry (newsletter editor) and Brent Kaplan (membership). Matt, Will, Meredith and Brent, your service is greatly appreciated! Anyone interested in filling one of these positions, or otherwise getting more involved with division leadership, please contact me at rvandrey@jhmi.edu.

Well, I think I have rambled on long enough... hope to see everyone in Minneapolis this summer!

-Ryan

Table of Contents

From the President's Desk.....	1
Table of Contents	2
Division 28 Presidential Candidate Statements.....	3
Statements from Candidates for Division 28 Member-at-Large	4
2022 APA Convention Update	5
2022 Division 28 Award Winners.....	7
MED Associates Brady-Schuster Award.....	7
Early Career Psychopharmacologist Award.....	8
Outstanding Dissertation Award.....	9
Welcome to our New Division 28 Members!.....	9
Populations Underrepresented in the Extramural Scientific Workforce: NIH Definitions	10
A Very Special Thank You to our Corporate Affiliates.....	12
New Fellows Nominations	13
Upcoming Events	13
<i>Psychopharmacology and Substance Use News</i> Editorial Policy.....	13
Division 28 Membership Information.....	14
<i>Experimental and Clinical Psychopharmacology Table of Contents</i>	15
<i>Experimental and Clinical Psychopharmacology Table of Contents</i>	16
Training and Employment Announcements.....	18
Division 28 Executive Committee	23

Division 28 Presidential Candidate Statements

Candidate statements are presented in alphabetical order

Jermaine Jones, Ph.D.

I am a research scientist and associate professor with the Division on Substance Use Disorders at Columbia University Medical Center. I completed my Ph.D. in Behavioral Neuroscience within the Psychopharmacology Laboratory at American University. As a graduate student my research investigated the rewarding and aversive effects of cocaine and alcohol in rodent models. In 2008 I joined Columbia's Division on Substance Use Disorders as a post-doctoral fellow. During this time, my work focused on clinical trials of novel medications for opioid use disorder and the interplay of factors that mediate and modulate the abuse potential of opioids. As an associate professor, my research seeks to incorporate genetic techniques into traditional human laboratory methodologies to improve our understanding of genetic involvement in substance use disorders. My current research also focuses on harm reduction strategies to combat opioid overdose, along with HIV prevention and care among methamphetamine users. I have been an active member of APA and Division 28 since I was a graduate student. I am also an alumnus of APA's predoctoral fellowship program. In 2020, I was granted Fellow status within APA through Division 28. Finally, in 2020 I was elected to APA's Board of Scientific Affairs and will be chair in 2023.



Mikhail N. Koffarnus, Ph.D.

I'm honored to be considered for the position of APA Division 28 President. Division 28 is a special organization that fosters a strong emphasis on mentorship and advocacy in addition to promoting psychopharmacological research. If elected, I would work to build upon these strengths, continuing and expanding upon the initiatives in these areas started by my predecessors. This would include efforts to recruit new members, promote mentorship and networking opportunities among existing members, and focus advocacy efforts on those that benefit our membership consisting largely of scientists engaged in psychopharmacology research. My own research has involved behavioral pharmacology, drug self-administration, behavioral economics, and novel treatments for substance use disorders. I direct the Healthier Futures Lab (HealthFuL) at the University of Kentucky, which aims to leverage behavioral economic principles to improve upon substance use disorder treatments. Within APA, I've been fortunate to work with our committed colleagues in Division 28 in multiple capacities over the years. I've been a Division 28 member and convention attendee continuously since 2011. APA



recently granted me Fellow status and named me to the APA Science Experts Network. My Division 28 executive committee service includes Newsletter Editor (2014 through 2016), Secretary (2017 through 2019), and I am currently Fellows Chair (2021 through 2023). I've been a Consulting Editor for *Experimental and Clinical Psychopharmacology* for over 8 years and also sit on the editorial boards of the *Journal of Experimental Analysis of Behavior* and *Psychology of Addictive Behaviors*.

Statements from Candidates for Division 28 Member-at-Large

Candidate statements are presented in alphabetical order

Cecilia L. Bergeria, Ph.D.

My name is Cecilia Bergeria and I am excited for the opportunity to run for member-at-large for Division 28. I am a behavioral pharmacologist by training and an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. My research focuses on the measurement, mechanisms, and treatment of opioid withdrawal and craving. I use a wide range of methodologies in my research, including human laboratory models of craving and withdrawal, qualitative interviews and focus groups, and behavioral economic demand analyses. I first attended APA as a graduate student in 2014 and I have routinely presented my data at the annual meeting. Further, I have collaborated with APA attendees within and outside of our Division to coordinate or participate in seven symposia. Topics for those symposia included: (1) understanding the role of pain among individuals with opioid use disorder, (2) developing FDA qualified drug development tools, and (3) the behavioral pharmacology of minor cannabinoids. In 2021, I served as the Division 28 program chair and coordinated the Division 28 poster session, symposia, invited lectures, and virtual live event for APA annual meeting attendees. I would be honored to continue my service to the Division as member-at-large, as Division 28 has been instrumental in facilitating countless career development opportunities for me. I am committed to creating more opportunities for early career researchers, promoting diversity in our membership, and advocating for substance use and psychopharmacology scientific advancement.



Dennis K. McBride, Ph.D.

Trained originally as an experimental psychologist, turned behavioral neuroscientist, I have served in many roles in my long career, from – government (including military), private, and nonprofit, to academic. Importantly, my government career of twenty years was in support of research and treatment for harmful substance use in the military. For the past several years I have served as Chief Scientist for a small but very successful pharmaceutical development firm (NRx Pharma), specializing in treatment of suicide-level bipolar depression (currently in FDA 2b/3 trials). We are credited with demonstrating the first biomarker of its kind in scientific psychiatry. As president of two high visibility public policy and



regulatory think tanks, and now as a government IPA, I interface routinely with Hill, White House and the judiciary on scientific psychological issues – I can/will support the Division leadership in the development and execution of strategy for our profession. I am also affiliated professor of practice in public policy at Virginia Tech – and affiliated professor at Georgetown University Medical Center. I am very encouraged about the future of our Division as thought leaders and change-makers via our APA. I would dearly love to serve our community, especially at this stage of my career and with the “tool box” that I have put together.

2022 APA Convention Update

Jacob Borodovsky, Ph.D.

Please join us for the 130th annual APA convention!

The convention will be *in-person* (with an additional virtual poster session) and will take place in Minneapolis, Minnesota from August 4th to 6th, 2022.

I'd like to thank all of the Division 28 members for submitting and reviewing our program submissions. We would not be able to develop such high-quality programming each year without the hard work of our reviewers.

This year's Division 28 program features some truly excellent, thought-provoking science spanning the wide range of timely topics and innovative questions currently being investigated by substance use and psychopharmacology researchers. The program will include divisional and co-sponsored symposia, posters, and skill-building sessions.



This year's divisional symposia include:

- Behavioral Economic Methods to Inform Cannabis Public Policy ← The disjointed patchwork of legal cannabis systems continues to expand while many of us trying to understand its effects are left scratching our heads. This is a skill-building session that will give attendees an extremely valuable, unifying, and evidence-based lens for thinking about aspects of the design and evaluation of legal cannabis laws, policies, and regulations.
- Pharmacology and Toxicology of Minor Cannabinoids: An Industry Collaborative Program of Research ← Cannabis is not just THC and CBD... there are over 100 distinct cannabinoids! Data from this symposium will bring us to the forefront of what we're learning about the lesser-known members of the cannabinoid universe like CBG, THCv, CBC, and CBN!
- The Promises and Perils of CBD Psychopharmacotherapy ← I don't know about you, but I feel like there are so many CBD papers being published now that I can barely keep track. I'm looking forward to getting up to date on what the data are telling us about CBD.
- Innovative Approaches to Using Cognitive Behavioral Therapy for Individuals with Opioid Use Disorder. ← 75,673 individuals in the US died of opioid overdoses last year. Think about that...75,673...We need new strategies for helping those struggling with OUD. This session is going to present recent advances in the types of innovative therapeutic approaches and concepts that are desperately needed.

- [Ketamine and Ketamine-Assisted Psychotherapy: An Overview of the Science and Issues Facing the Field](#) ← A form of Ketamine is now an FDA-approved medication, but there are a lot of open questions about this new and unexplored territory. This session is going to bring us up to speed on the recent history of ketamine as a medication, data from the major trials, and how treatment protocols are being implemented in the US.

Additionally our colleagues in Divisions 6, 50, and 55, are holding a number of sessions co-listed with Division 28 that you won't want to miss such as:

- [Public support for overdose prevention programs: How to overcome misconceptions](#)
- [Propranolol as a modulator of trauma-related memory in comorbid PTSD and alcohol dependence: A proof of concept study](#)
- [A therapeutic role for the \(5-HT\) 5-HT_{2A} receptor \(5-HT_{2AR}\) and 5-HT_{2CR} to reduce the reinforcement value of oxycodone in male Sprague-Dawley rats](#)
- [What's new in psychopharmacology: FDA-approvals and treatments on the horizon](#)
- [Exploring social factors contributing to natural recovery from substance addiction](#)
- [Substance use prevention messaging for youth during COVID-19](#)
- [Event-related potential \(ERP\) and event-related spectral perturbation \(ERSP\) signatures of salience attribution to alcohol cues](#)
- [Understanding poly-substance abuse: Differential effects of nicotine and alcohol on neuroimmune function may underlie co-use](#)

We are also holding our in-person and virtual poster sessions as well as several award presentations to highlight the outstanding researchers who are making valuable contributions to our field. This includes the NIDA/NIAAA early career poster session and social hour (co-sponsored by Division 28 and Division 50), which is an excellent networking opportunity for young researchers (and it's catered!).

In addition, current Division 28 President Ryan Vandrey will give his Presidential Address on the current state of cannabis science and product regulation.

The dates/times of each session are forthcoming. However, please start thinking about your travel arrangements now.

I know we all got used to virtual conferences over these past couple of years, but I think it will be great to see everyone and talk science for a few days!

The APA conference registration is open: <https://convention.apa.org/>

As always, please reach out with any questions: Jacob.Borodovsky@dartmouth.edu

2022 Division 28 Award Winners

Richard Yi, Ph.D.

Please join me in congratulating our 2022 Division 28 Award Winners! We had excellent candidates nominated in all categories, and I would like to thank all the nominees and those who nominated them for their participation this year. Division 28 has an outstanding roster of early career and senior scientists doing excellent work. Now, for our winners!

MED Associates Brady-Schuster Award



John Roll, Ph.D.

Professor and Vice Dean for Research
Elon S. Floyd College of Medicine
Washington State University

This award honors a mid-career or senior scientist (at least 15 years after doctoral degree) who conducts outstanding research underscoring the fundamental importance of behavioral science to psychopharmacology or substance use. This year's winner is **John Roll, Ph.D.**

Dr. John Roll earned a Bachelor of Arts degree from the University of Montana, a Master of Arts degree from Saint Bonaventure University, and a PhD from Washington State University. He completed a Postdoctoral Fellowship in Behavioral Pharmacology at the

University of Vermont and a Postdoctoral Fellowship in Substance Abuse Research at the University of Michigan Ann Arbor. He has served as a faculty member in the Department of Psychiatry at Wayne State University, Director of Behavioral Pharmacology in UCLA's Integrated Substance Abuse Programs, Director of the Washington Institute for Mental Health Research and Training, Associate Dean for Research in the Washington State University (WSU) College of Nursing, Associate Vice Provost for Health Sciences at WSU, Senior Vice Chancellor for Academic Affairs and Research at the WSU Health Sciences Campus, and Associate Vice President for Health Sciences Research. He is currently Professor and Vice Dean for Research in the Elson S. Floyd College of Medicine and the Acting Chair of the Community and Behavioral Health department. He is the Founding Director of the WSU Program of Excellence in Addictions Research and is the Director of the WSU Translational Addiction Research Collaborative. Dr. Roll also founded the Rural Mental Health and Substance Abuse Treatment Center.

Dr. Roll has enjoyed faculty appointments in the WSU Departments of Medicine, Psychology, Neuroscience, Nursing, Prevention Science, Nutrition Exercise and Physiology and Health Policy Administration. He was appointed by Washington State Governor Gregoire as a Vice Chair of the Governor's Council on Substance Abuse and as an Executive Commissioner on the Eastern State Hospital Advisory Board. Dr. Roll has served on review committees for various agencies including the National Institutes of Health, Centers for Disease Control and Prevention, and Substance Abuse and Mental Health Services Administration. Roll is a Fellow of the following organizations: American Psychological Association (3 Divisions), Association for Behavior Analysis International, Association for Psychological Science, and the American Association for the Advancement of Science. He is the newly elected President of the Washington State Academy of Sciences. He has published nearly 200

scholarly articles which have been cited more than 7,977 times as of April 2022. He is a recipient of the Distinguished Contribution to Applied Behavioral Research Award from the American Psychological Association and was awarded the WSU 2022 Sahlin Eminent Faculty Award. He has been a mentor to many graduate students, postdoctoral fellows, and junior faculty. Dr. Roll serves, or has served, on the following Boards: Northwest Association for Biomedical Research, Spokane Regional Health District Community Health Assessment Board, Better Health Together Leadership Council, a member of SAMHSA's "Stimulant Technical Expert Panel" and the Bree Collaborative on Opioid Use Treatment Group. He also serves on local civic, educational, and business boards. He is a current member of SAMHSA's Mental Health and Addiction Technology Transfer Center's Boards.

Early Career Psychopharmacologist Award



Lorenz S. Neuwirth, Ph.D.

Assistant Professor, The State University of New York (SUNY) Old Westbury

This award honors an early career scientist conducting original, meritorious work in psychopharmacology and encourages excellence in research at the interface between the disciplines of pharmacology and psychology. This year's winner is **Lorenz S. Neuwirth, PhD**. Dr. Neuwirth's research focuses on characterizing the effects of neurodevelopmental lead exposure in rodent models and how it causes sex-dependent differences in fronto-executive functions that persist as developmental neuropathies across the lifespan. Lead poisoning remains a persistent problem negatively impacting

children that live in houses and apartments that still contain lead-based paints, residing near industrial manufacturing buildings, e-waste recycling, and/or superfund sites, and consuming water or food and drinks that are lead contaminated.

Dr. Neuwirth's work has also identified a promising psychopharmacological treatment for ameliorating lead poisoning through taurine and its derivatives in which he filed a patent. Dr. Neuwirth's work has found that taurine works on increasing the excitability through the NMDA receptors, that are associated with learning and memory, to increase cognition (as a nootropic property) and by increasing the inhibition through the GABA-A receptors, which are associated with stabilizing the proper rates of attentional processing speeds allowing for more sustained and focused attention as well as reducing anxiety-like traits (as an anxiolytic property). Taken together, this dual psychopharmacological treatment serves to reduce the intellectual disability and hyperactivity/impulsivity profile in lead-exposed rats to levels near that of a non-lead-exposed rat. Ultimately, it is Dr. Neuwirth's goal that this line of research will allow for the identification of specific derivatives of taurine to be used to treat sex-specific and developmental time-period dependent (i.e., gestational, perinatal, and early postnatal) neurobiological deficits induced by lead poisoning, and to assess the prospects of its bio-medical translational through overseeing clinical studies in children that have been diagnosed with lead poisoning.

Outstanding Dissertation Award

Cassie L. Boness, Ph.D.

Assistant Research Professor
Center on Alcohol, Substance use, and Addictions
University of New Mexico

This award honors the best doctoral dissertations in psychopharmacology and substance use research.

This year's winner is **Cassie Boness, Ph.D. Dr. Cassandra Boness** is a licensed clinical psychologist and Research Assistant Professor at the University of New Mexico's Center on Alcohol, Substance use, and Addictions. Her mixed-methods research, guided by the primary goal of reducing harm and suffering in the lives of people with substance use disorders, focuses on the etiology, assessment, and treatment of alcohol use disorder. Dr. Boness is particularly interested in developing and refining the assessment of alcohol use disorder mechanisms with the eventual goal of facilitating mechanism-based precision medicine. Clinically, she specializes in motivational interviewing and has a strong background working with Deaf and Hard of Hearing communities. She is passionate about improving diversity, equity, and inclusion in psychological science.



Welcome to our New Division 28 Members!

We are very stoked to welcome several new members to the division! We are excited to get to know our new members. If you are a new member and would like to be introduced in the newsletter, please contact Brent Kaplan (brentkaplan@uky.edu).

New Members are presented in alphabetical order.

Marcel O. Bonn-Miller received his B.A. and Ph.D. in Clinical Psychology from the University of Vermont and completed internship and postdoc at VA Palo Alto and Stanford University. Dr. Bonn-Miller's research is focused on the intersection between cannabis and a number of physical and psychological conditions and symptoms. After 9 years working at the VA, Marcel transitioned to industry where he first worked at Zynerva Pharmaceuticals, a company focused on transdermal cannabinoid drug development, and now serves as Vice President of Human and Animal Research at Canopy Growth Corporation. At Canopy Growth Corporation, Marcel oversees innovative research on topics ranging from cannabinoid safety to human pharmacokinetics and effects of understudied cannabinoids and cannabinoid combinations across varying formulations and routes of administration.



Hi. I'm Dr. Taylor, a board certified general psychiatrist with the ABPN and a board certified addiction medicine (addictionologist) specialist with the ABPM. I am the medical director of Second Chances Addiction Recovery Center in Rayville, LA. Forever a student, I'm in the final semester of my masters in general psychology at NCU. I will then apply to their PhD program in addiction psychology. Glad to be here as a new member!



Populations Underrepresented in the Extramural Scientific Workforce: NIH Definitions

Meredith Berry, Ph.D.

This column serves as a reminder of the scope of NIH definitions for populations underrepresented in the scientific workforce. These definitions may serve as helpful reminders for hiring committees and scientists at all levels (e.g., qualifications for diversity supplements offered by NIH) as we work to increase diversity and representation in our fields.

- Individuals from racial and ethnic groups that have been shown by the National Science Foundation to be underrepresented in health-related sciences on a national basis (visit [nsf.gov](https://www.nsf.gov) to see **data** and the report "**Women, Minorities, and Persons with Disabilities in Science and Engineering**").
- In addition, it is recognized that underrepresentation can vary from setting to setting; individuals from racial or ethnic groups that can be demonstrated convincingly to be underrepresented by the grantee institution should be encouraged to participate in NIH programs to enhance diversity. For more information on racial and ethnic categories and definitions, see the **Explanation of Data Standards for Race, Ethnicity, Sex, Primary Language, and Disability**.
- Individuals with disabilities, who are defined as those with a physical or mental impairment that substantially limits one or more major life activities, as described in the **Americans with Disabilities Act of 1990, as amended**. See NSF data [here](#).

Individuals from disadvantaged backgrounds, defined as those who meet two or more of the following criteria:

- Were or currently are homeless, as defined by the McKinney-Vento Homeless Assistance Act (Definition: <https://nche.ed.gov/mckinney-vento/>);
- Were or currently are in the foster care system, as defined by the Administration for Children and Families (Definition: <https://www.acf.hhs.gov/cb/focus-areas/foster-care/>);

- Were eligible for the Federal Free and Reduced Lunch Program for two or more years (Definition: <https://www.fns.usda.gov/school-meals/income-eligibility-guidelines>);
- Have/had no parents or legal guardians who completed a bachelor's degree (see <https://nces.ed.gov/pubs2018/2018009.pdf>);
- Were or currently are eligible for Federal Pell grants (Definition: <https://www2.ed.gov/programs/fpg/eligibility.html>);
- Received support from the Special Supplemental Nutrition Program for Women, Infants and Children (WIC) as a parent or child (Definition: <https://www.fns.usda.gov/wic/wic-eligibility-requirements>).
- Grew up in one of the following areas: a) a U.S. rural area, as designated by the Health Resources and Services Administration (HRSA) **Rural Health Grants Eligibility Analyzer**, or b) a **Centers for Medicare and Medicaid Services-designated Low-Income and Health Professional Shortage Areas** (qualifying zipcodes are included in the file). Only one of the two possibilities listed can be used as a criterion for the disadvantaged background definition.

Students from low socioeconomic (SES) status backgrounds have been shown to obtain bachelor's and advanced degrees at significantly lower rates than students from middle and high SES groups (see https://nces.ed.gov/programs/coe/indicator_tva.asp), and are subsequently less likely to be represented in biomedical research. For background see Department of Education data at, <https://nces.ed.gov/>; https://nces.ed.gov/programs/coe/indicator_tva.asp; <https://www2.ed.gov/rschstat/research/pubs/advancing-diversity-inclusion.pdf>.

Literature shows that women from the above backgrounds face particular challenges at the graduate level and beyond in scientific fields. (See, e.g., "**From the NIH: A Systems Approach to Increasing the Diversity of Biomedical Research Workforce**")

Women have been shown to be underrepresented in doctorate-granting research institutions at senior faculty levels in most biomedical-relevant disciplines, and may also be underrepresented at other faculty levels in some scientific disciplines (See data from the **National Science Foundation National Center for Science and Engineering Statistics: Women, Minorities, and Persons with Disabilities in Science and Engineering**).

Upon review of NSF data, and scientific discipline or field related data, NIH encourages institutions to consider women for faculty-level, diversity-targeted programs to address faculty recruitment, appointment, retention or advancement.

A Very Special Thank You to our Corporate Affiliates



For more on Friends Research Institute, please visit their website: <https://friendsresearch.org/>



For more on Ashley, please visit their website: <https://www.ashleytreatment.org/>

Pinney Associates

For more on Pinney Associates, please visit their website: <https://www.pinneyassociates.com/>



For more on Med Associates Inc., please visit their website: <https://www.med-associates.com/>



For more on Harrison assessments, please visit their website: <https://www.harrisonassessments.com/>

New Fellows Nominations

Mikhail Koffarnus, Ph.D.

Division 28 is seeking nominations for new Fellows. As described by APA, “Fellow status is an honor bestowed upon APA members who have shown evidence of unusual and outstanding contributions or performance in the field of psychology. Fellow status requires that a person's work has had a national impact on the field of psychology beyond a local, state, or regional level. A high level of competence or steady and continuing contributions are not sufficient to warrant fellow status. National impact must be demonstrated.”

In Division 28 a successful nominee will typically be 10-15 years post-doctorate, have a minimum of 30 publications and a track record of external funding, and can document national impact of her or his research.

If you would like to nominate a colleague for consideration for Fellow status, please send her or his CV and contact information to the address below. You may also nominate somebody who is already an APA Fellow (with relevance to our Division), but who is not yet a Fellow of Division 28. Self-nominations are also welcomed.

Contact Information for Fellow Nominations:

Mikhail Koffarnus, Ph.D.

Division 28 Fellows Chair

Email: koffarnus@uky.edu



Upcoming Events

Meredith Berry, Ph.D.

2022 Annual APA Convention

The 130th annual American Psychological Association convention is scheduled to be held in-person, August 4-6, 2022. Please visit <https://convention.apa.org/> for more details and registration information.

Please visit the APA Division 28 [News and Events](#) section of our website to learn about other upcoming events and meetings. To submit an announcement of an upcoming event to the website and/or newsletter, please send all information or flyers to the newsletter editor, Meredith Berry (mberry@ufl.edu).



Psychopharmacology and Substance Use News Editorial Policy

Psychopharmacology and Substance Use News is a thrice-yearly publication of Division 28. It is devoted to keeping its members informed about the activities of Division 28 and to news and comments concerning all aspects of psychopharmacology and substance use. Articles, comments, announcements, and advertisements should be sent to the editor, Meredith Berry (mberry@ufl.edu).

You can also read content from archived Division 28 newsletters [here](#).



Division 28 Membership Information

Brent Kaplan, Ph.D.

Individual Memberships

Division 28 is committed to:

- Basic and Applied Research
- Undergraduate, Graduate, and Postdoctoral training
- Evidenced-based Clinical Practice
- Public Service and Advocacy

We accept APA members and non-members, and have different membership levels available for students, early career psychologists (terminal degree within the past 7 years), and regular members.



Members receive a thrice-yearly newsletter, and are eligible for 1 of 3 annual awards (Outstanding Dissertation, Early Career Psychopharmacologist, Med Associates Brady/Schuster Award). See the previous award winners at our Division 28 [awards page](#)!

Please consider joining or renewing your membership this year. Contact our membership chair Brent Kaplan (brentkaplan@uky.edu) or visit our Division 28 [membership page](#) on our website for more information!

Corporate Affiliate Memberships

Corporate contributions support efforts in research, practice, and education. A membership contribution of \$1000 is tax deductible.*

Division 28 is pleased to offer the following benefits to our corporate affiliate members:

- Access to thrice yearly newsletter
- Acknowledgement of support with corporate logo in newsletter
- Newsletter acknowledgement hyperlinked to corporate website, and available to all through newsletter posting on the Division 28 website
- Recognition of corporate support at annual APA membership meeting
- Liaison(s) eligible to subscribe to Division members-only listserv
- Liaison(s) participation in active and growing Division 28 social media presence
- Receive overview of relevant programming at APA convention

Please refer to the website for questions regarding Division 28 [Corporate Affiliate Membership](#) or contact:

Dr. Ryan Vandrey (Division 28 President) at rvandrey@jhmi.edu

Or

Dr. Will Aklin (Division 28 Treasurer) at aklinwm@nida.nih.gov

**This is the recommended level of support. Any corporate contributions are tax exempt, and our tax number will be supplied upon request. Other levels of support are available.*

Experimental and Clinical Psychopharmacology

TABLE OF CONTENTS: 2022 | VOLUME 30 | ISSUE 1 (February)

Editor: William Stoops, Ph.D.

1. [Pregestational oxycodone exposure does not impact future maternal care or drug preference in the postpartum mouse.](#)
Pages 1-14. Watters, Amanda B.; Sands, L. Paul; Cammack, Katharine M.
2. [Utility of a brief assessment of opioid demand among post-discharge trauma care patients.](#)
Pages 15-22. Yoon, Jin H.; Suchting, Robert; Kessler, Danielle; Soder, Heather E.; Kapoor, Shweta; Stotts, Angela L.; Heads, Angela M.; Harvin, John A.; Green, Charles E.; Lane, Scott D.; Schmitz, Joy M.
3. [Anxiety sensitivity and opioid use motives among adults with chronic low back pain.](#)
Pages 23-30. Rogers, Andrew H.; Garey, Lorra; Raines, Amanda M.; Allan, Nicholas P.; Schmidt, Norman B.; Zvolensky, Michael J.
4. [Bidirectional influence of heroin and cocaine escalation in persons with dual opioid and cocaine dependence diagnoses.](#)
Pages 31-38. Butelman, Eduardo R.; Chen, Carina Y.; Lake, Kimberly J.; Brown, Kate G.; Kreek, Mary Jeanne.
5. [Effects of substance use on monetary delay discounting among people who use stimulants with and without HIV: An ecological momentary assessment study.](#)
Pages 39-50. Xu, Yunan; Towe, Sheri L.; Causey, Shakiera T.; Dennis, Paul A.; Meade, Christina S.
6. [Parallel growth modeling to better understand smoking with stimulant use outcomes during an integrated treatment trial.](#)
Pages 51-58. Mamey, Mary R.; Burns, G. Leonard; Barbosa-Leiker, Celestina; Smith, Crystal Lederhos; McPherson, Sterling.
7. [The phenotype of recovery II: The association between delay discounting, self-reported quality of life, and remission status among individuals in recovery from substance use disorders.](#)
Pages 59-72. Athamneh, Liqa N.; Freitas Lemos, Roberta; Basso, Julia C.; Tomlinson, Devin C.; Craft, William H.; Stein, Madison D.; Bickel, Warren K.
8. [Why adolescents engage in early alcohol use: A study of drinking motives.](#)
Pages 73-81. Smit, Koen; Voogt, Carmen; Otten, Roy; Kleinjan, Marloes; Kuntsche, Emmanuel.
9. [Can exercise alleviate sleep disturbances during acute nicotine withdrawal in cigarette smokers?](#)
Pages 82-92. Soreca, Isabella; Conklin, Cynthia A.; Vella, Elizabeth J.; Salkeld, Ronald P.; Joyce, Christopher J.; Mumma, Joel M.; Jakicic, John M.; Kupfer, David J.
10. [Toward a new predoctoral model: Education and training in clinical psychopharmacology.](#)
Pages 93-105. Rodriguez-Menendez, Gerardo; Shelton, Sarah; Steinman, Judith; Barr, Michael; Cunningham, Alyssa; Glaser, Dina; Masson, Tiffany; McGrath, Breeda; Nealon, Michele; Bray, James H.; DeLeon, Patrick; Moore, Bret A.; Rom-Rymer, Beth N.

11. [Association of *SAPAP3* allelic variants with symptom dimensions and pharmacological treatment response in obsessive-compulsive disorder.](#)
Pages 106-112. Naaz, Safoora; Balachander, Srinivas; Srinivasa Murthy, Nithyananda; MS, Bhagyalakshmi; Sud, Reeteka; Saha, Priyanka; Narayanaswamy, Janardhanan C.; Reddy YC, Janardhan; Jain, Sanjeev; Purushottam, Meera; Viswanath, Biju.
12. [Behavioral economic assessment of abuse liability for Black & Mild cigar flavors among young adults.](#)
Pages 113-119. Bono, Rose S.; Cobb, Caroline O.; Wall, Catherine S.; Lester, Rebecca C.; Hoetger, Cosima; Lipato, Thokozeni; Guy, Mignonne C.; Eissenberg, Thomas; Bickel, Warren K.; Barnes, Andrew J.
13. [Alcohol demand and supersized alcopop consumption among undergraduate college students.](#)
Pages 120-125. Olson, Mackenzie L.; Rossheim, Matthew E.; Sanders, Sadie B.; Yurasek, Ali M.

Experimental and Clinical Psychopharmacology

TABLE OF CONTENTS: 2021 | VOLUME 29 | ISSUE 6 (December)

Editor: William Stoops, Ph.D.

1. [PKC inhibition decreases amphetamine-maintained responding under a progressive-ratio schedule of reinforcement.](#)
Pages 567-572. Altshuler, Rachel D.; Mac, Ryan C.; Gnegy, Margaret E.; Jutkiewicz, Emily M.
2. [Differences in serum orexin-A levels between the acute and subacute withdrawal phases in individuals who use methamphetamine.](#)
Pages 573-579. Lee, Wan-Chen; Chen, Po-Yu; Kao, Chung-Feng; Huang, Ming-Chyi.
3. [Predicting college student prescription stimulant misuse: An analysis from ecological momentary assessment.](#)
Pages 580-586. Schepis, Ty S.; Buckner, Julia D.; Klare, Dalton L.; Wade, Lauren R.; Benedetto, Natalie.
4. [Both reducing cigarettes per day and transitioning to very low-nicotine-content cigarettes decreases demand for usual-brand cigarettes.](#)
Pages 587-592. Nighbor, Tyler D.; Klemperer, Elias M.; Hughes, John R.; Reed, Ellaina N.; Simone, Samuel J.; West, Julia C.
5. [Increasing cessation motivation and treatment engagement among smokers in pain: A pilot randomized controlled trial.](#)
Pages 593-604. Zale, Emily L.; Maisto, Stephen A.; De Vita, Martin J.; Hooten, W. Michael; Ditre, Joseph W.
6. [The relative impact of acute nicotine and tobacco administration on craving, withdrawal, and cigarette self-administration in dependent and nondependent smokers.](#)
Pages 605-614. Spinella, Toni C.; Barrett, Sean P.; Schlagintweit, Hera E.
7. [The effects of inhaled flavors on intravenous nicotine.](#)
Pages 615-624. MacLean, R. Ross; Gueorguieva, Ralitzia; DeVito, Elise E.; Peltier, MacKenzie R.; Parida, Suprit; Sofuoglu, Mehmet.

8. [Tobacco-use behavior and toxicant exposure among current dual users of electronic cigarettes and tobacco cigarettes.](#)
Pages 625-635. Cobb, Caroline O.; Lester, Rebecca C.; Rudy, Alyssa K.; Hoetger, Cosima; Scott, Megan; Austin, Makeda; Montpetit, Alison; Lipato, Thokozeni; Graham, Amanda L.; Barnes, Andrew J.; Eissenberg, Thomas.
9. [Establishing preclinical withdrawal syndrome symptomatology following heroin self-administration in male and female rats.](#)
Pages 636-649. Gipson, Cassandra D.; Dunn, Kelly E.; Bull, Amanda; Ulangkaya, Hanaa; Hossain, Aronee.
10. [Caffeine consumption, toxicity, tolerance and withdrawal; shared genetic influences with normative personality and personality disorder traits.](#)
Pages 650-658. Czajkowski, Nikolai; Kendler, Kenneth S.; Torvik, Fartein Ask; Ystrom, Eivind; Rosenström, Tom; Gillespie, Nathan A.; Reichborn-Kjennerud, Ted.
11. [The role of substance use coping in linking depression and alcohol use from late adolescence through early adulthood.](#)
Pages 659-669. Magee, Kelsey E.; Connell, Arin M.
12. [The language of subjective alcohol effects: Do young adults vary in their feelings of intoxication?](#)
Pages 670-678. Linden-Carmichael, Ashley N.; Allen, Hannah K.; Lanza, Stephanie T.
13. [Further validation of the Treatment Self-Regulation Questionnaire for assessing motivations for responsible drinking: A test of self-determination theory.](#)
Pages 679-688. Richards, Dylan K.; Pearson, Matthew R.; Field, Craig A.
14. [Sex-dependent effects of alcohol administration on the urge to use cannabis.](#)
Pages 689-695. Venegas, Alexandra; Meredith, Lindsay R.; Green, ReJoyce; Cooper, Ziva D.; Ray, Lara A.
15. [A systematic review and meta-analysis of delay discounting and cannabis use.](#)
Pages 696-710. Strickland, Justin C.; Lee, Dustin C.; Vandrey, Ryan; Johnson, Matthew W.
16. [Sexual discounting: A systematic review of discounting processes and sexual behavior.](#)
Pages 711-738. Johnson, Matthew W.; Strickland, Justin C.; Herrmann, Evan S.; Dolan, Sean B.; Cox, David J.; Berry, Meredith S.
17. [Behavioral economics of substance use: Understanding and reducing harmful use during the COVID-19 pandemic.](#)
Pages 739-749. Acuff, Samuel F.; Tucker, Jalie A.; Murphy, James G.
18. [Compounded intranasal racemic ketamine for major depressive disorder: A case report.](#)
Pages 750-754. Ziegler, Lindsey; Peters, Evyn; Wanson, Annabelle; Halpape, Katelyn.

Training and Employment Announcements

VERMONT CENTER ON BEHAVIOR AND HEALTH POSTDOCTORAL RESEARCH FELLOWSHIPS

The Vermont Center on Behavior and Health (VCBH) located at the University of Vermont (UVM) Larner College of Medicine (LCOM) announces **THREE** NIH postdoctoral research fellowship opportunities in our internationally-recognized center of excellence in tobacco and substance use disorder research.

Working with **Dr. Stacey Sigmon**, the fellow will help to lead ongoing randomized clinical trials evaluating low-barrier, technology-assisted buprenorphine treatment for individuals with opioid use disorder (OUD), as well as develop new research opportunities aimed at expanding OUD treatment access in rural, underserved areas.

Working with **Dr. Diann Gaalema**, the fellow will participate in the conduct of an ongoing NIDA/FDA-funded trial on the use of tobacco in vulnerable populations, including people with affective disorders, as well as work on and develop new research opportunities within the area of tobacco use in cardiac patients.

Working with **Dr. Andrea Villanti**, the fellow will assist with ongoing population studies related to youth and young adult tobacco and substance use and vaping prevention, and randomized controlled trials of nicotine messaging. The fellowship will include secondary analysis of cohort and trial data to inform public health programs and policy, with opportunities to develop new research projects in ongoing and pilot studies.

Drs. Sigmon, Gaalema and Villanti, VCBH colleagues, and our 30-year training program have an exceptional track record of helping fellows to establish successful careers as independent investigators.

Eligibility: Applicants must have completed their training in psychology or a related discipline and be U.S. citizens or permanent residents. Outstanding trainees are selected on the basis of scholastic record, productivity and commitment to a career in substance use disorder research. Individuals must be highly motivated, possess initiative, and have a strong desire to learn and expand their interests and expertise.

Appointment: 2-3 yrs

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Sarah Heil (sarah.heil@uvm.edu). Please indicate which faculty member(s) you are interested in working with in your cover letter.

For more information: Contact Ms. Nicole C. Twohig (Nicole.twohig@uvm.edu) or visit our website (www.med.uvm.edu/behaviorandhealth).

About us: VCBH, established in 2013, is an interdisciplinary center of research excellence committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death. Unhealthy, or risk behaviors, are overrepresented among socioeconomically disadvantaged populations and are

major contributors to the problem of health disparities. VCBH's work seeks to develop effective interventions and policies to promote healthy behavior. The VCBH resides within the UVM LCOM Department of Psychiatry, with additional investigators, collaborators, and advisors across 15 LCOM academic departments, seven UVM colleges, and five other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels.

Burlington, Vermont is located in the beautiful Lake Champlain region and has continually been voted one of the nicest cities in which to live as well as one of America's most "fit" cities due to the four seasons of outdoor activities. Burlington is a great place for families, boasting excellent schools, a culturally-rich environment, and close proximity to Boston and Montreal.

The University is especially interested in candidates who can contribute to the diversity and excellence of the academic community through their research, teaching, and/or service. Applicants are requested to include in their cover letter information about how they will further this goal.

The University of Vermont is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other category legally protected by federal or state law. The University encourages applications from all individuals who will contribute to the diversity and excellence of the institution. Applications will be accepted until the positions are filled.

JOHNS HOPKINS UNIVERSITY POSTDOCTORAL RESEARCH FELLOWSHIPS IN SUBSTANCE ABUSE AND PSYCHOPHARMACOLOGY HUMAN RESEARCH TRAINING

Postdoctoral research fellowships available in a stimulating, productive program with excellent resources. Prepare to be an independent investigator.

HUMAN LABORATORY -- behavioral & clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive/ memory function, impulsivity, neuroimaging); anti-drug abuse medication development; behavioral research related to addiction: delay discounting, behavioral economics, and sexual risk behavior. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine, hallucinogens, psilocybin, salvinorin A, MDMA, methamphetamine.

CLINICAL TRIALS - testing medications, behavioral therapies (especially incentive/contingency-based), and combinations; psychiatric comorbidity research; addiction & pregnancy/women; therapeutic applications for psilocybin (cancer anxiety & smoking cessation). Opioid, cocaine, tobacco, mixed/other dependencies

Eligibility: U.S. citizen, permanent resident. Many backgrounds are appropriate, including experimental or clinical psychology, pharmacology, psychiatry, neuroscience, public health, and social work. Background in human or nonhuman research is appropriate

NIH stipend levels: \$37,000 to \$51,000

Start Date: Flexible.

Faculty: George Bigelow, Roland Griffiths, Maxine Stitzer, Eric Strain, Kenneth Silverman, Robert Brooner, Miriam Mintzer, Una McCann, Ryan Vandrey, Matthew Johnson, Kelly Dunn, David Thompkins, Denis Antoine, Fred Barrett

To apply: Contact George Bigelow; BPRU, Behavioral Biology Research Center; 5510 Nathan Shock Drive; Johns Hopkins Bayview Campus; Baltimore, Maryland 21224-6823. (410) 550-003, bigelow@jhmi.edu. For more information see www.bpru.org.

UNIVERSITY OF KENTUCKY, COLLEGE OF MEDICINE POSTDOCTORAL FELLOW

The University of Kentucky College of Medicine Department of Behavioral Science is seeking applicants for a post-doctoral fellowship. This is a two-year fellowship, with an optional third year, funded by National Institute on Drug Abuse (NIDA) T32 that is designed to train researchers in behavioral aspects of substance use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.

For further application details, please email Dr. Craig Rush (crush2@uky.edu).

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO POSTDOCTORAL FELLOWSHIP

The Substance Abuse Research Program at the University of California, San Francisco is currently accepting applications to its two-year postdoctoral research training program. This program, funded by a National Institute on Drug Abuse (NIDA) T32 grant, aims to produce the next generation of leaders in the field of drug abuse treatment and services research. With the support of faculty mentors, scholars design and implement studies on treatment of drug and alcohol dependence. Current research interests of faculty include trials of efficacy and effectiveness of psychosocial and pharmacologic treatment of drug abuse, including:

- Tobacco dependence and food insecurity
- Innovative methodology including Internet-based studies
- Treatment of complex patients in innovative settings
- Diagnostic techniques and research on treatment tailored for HIV-positive drug abusers and drug abusers with psychiatric and medical disorders
- Provision of services to drug and alcohol abusing populations



- Instrument development in drug abuse

A variety of university-affiliated and community substance abuse programs are available as research sites. These include inpatient and outpatient setting programs that treat a range of problems related to drugs of abuse, including dependence on cocaine, nicotine, alcohol, and opiates. Our program encourages close research involvement with your preceptor, and involvement in selected classes, seminars, and grant preparation. Resources from other significant extramural funding and R01-level grants are also routinely available to scholars. Funds for travel and training opportunities are available.

More information can be found at:
<http://psych.ucsf.edu/SUDTSR>

To Apply: Submit a cover letter, curriculum vitae, statement of research interests, and representative work or dissertation chapters, and 2 letters of reference to: jaime.smith@ucsf.edu. Applicants must have completed their doctoral degree and be a U.S. citizen or have Lawful Permanent Residency (green card) status at the time of appointment. Letters of reference should be sent directly from the recommenders to Ms. Adem.

Jaime Smith, CCRP, Division Administrator
Substance Abuse Research Program
ZSFG Psychiatry, UCSF School of Medicine
jaime.smith@ucsf.edu

UNIVERSITY OF CALIFORNIA, SAN DIEGO POSTDOCTORAL FELLOWSHIP

The Department of Family Medicine and Public Health at the University of California, San Diego is seeking a post-doctoral researcher in epidemiology, economics, and policy research on drug use and abuse. This position is funded through awards from TRDRP (Tobacco-related Disease Research Program) and NIH/NIDA (National Institute on Drug Abuse). The one- to three-year position is immediately available.

The selected fellow will work closely with Dr. Yuyan Shi on projects about policy, economic, and neighborhood environments related to marijuana, tobacco, opioid, and other drugs. The candidate will also have opportunities to work with other inter-disciplinary researchers in the larger network of public health. Department of Family Medicine and Public Health at School of Medicine provides a multi-disciplinary and stimulating environment to prepare the candidate towards an independent career.

Applicants should have a doctorate in public health or social science (health services, health economics, health policy, community health, social work, behavioral medicine, psychology, epidemiology, urban studies, and other public health related fields). The ideal candidate will have strong quantitative skills, including prior experience in using statistical packages and analyzing large-scale population surveys or administrative records. Demonstrated ability to apply spatial analysis tools such as ArcGIS, or develop and implement survey questionnaires, or design and implement behavioral economics experiments will be an advantage. Strong writing and communication skills are also expected.

The University of California, San Diego is an Equal Opportunity/Affirmative Action Employers. Minorities and

women are strongly encouraged. U.S. citizen or permanent resident is preferred but not required. Visa sponsorship will be provided if needed. Applications will be considered until the position is filled. Interested candidates should submit a curriculum vitae, a cover letter describing research interests and experience, one writing sample, and three names of references to Dr. Yuyan Shi at yus001@ucsd.edu.

UNIVERSITY OF TEXAS, MCGOVERN MEDICAL SCHOOL POSTDOCTORAL FELLOWSHIP

The Department of Psychiatry and Behavioral Sciences, UTHealth Medical School in Houston, is recruiting outstanding Ph.D. clinician scientists for Postdoctoral Fellowship opportunities. We seek well-trained, motivated individuals with excellent communication and interpersonal skills, demonstrated proficiency in scientific writing, and the **desire to learn the necessary skills to transition into independent faculty positions**. The training period involves two years starting in September or October 2019. **A key focus for the training period will be the development of successful grant planning and writing skills pursuant to applications to NIH, NSF and private foundations.**

NIH-funded investigators in the Department will serve as mentors. Current work focuses on treatment outcomes, clinical trials, behavioral interventions (Dr. Joy Schmitz), human behavioral processes, neuroimaging and psychopharmacology (Dr. Scott Lane), molecular, genetic/epigenetics (Dr. Consuelo Walss-Bass), neuroimaging, cognitive neurosciences (Dr. Jair Soares), Bayesian statistics, data science, novel adaptive trial designs (Dr. Charles Green). Training and/or interest in any of these areas is welcomed, but we strongly emphasize team science and thus preference will be given to individuals seeking translational training across these domains. The department has strengths in clinical service and clinical research, particularly in the fields of substance use disorders and mood disorders. Our clinical research programs are housed at the state-of-the-art **Behavioral and Biomedical Sciences Building (BBSB)** and the **UT Harris County Psychiatric Center**, one of the largest inpatient academic psychiatric hospitals in the US with 250 acute care psychiatric beds.

UTHealth is an integral part of the Texas Medical Center (TMC), the largest medical center in the world, with a vibrant academic community and a plethora of outstanding collaborative and translational opportunities in the health sciences. Houston is the 4th largest US metropolitan area featuring continued growth and economic prosperity, vibrant opportunities, and a highly competitive cost of living relative to other culturally diverse metropolitan areas. Applicants must have completed a Ph.D or equivalent degree. Preference given to those with training or experience in programs with active NIH grant portfolios. Competitive salaries and benefits are available. To find out more information about these unique academically-driven positions or to apply, please forward a CV and letter of interest to **Joy M. Schmitz, Ph.D., Professor and Director of the Center for Neurobehavioral Research on Addiction (CNRA)**, e-mail: Joy.M.Schmitz@uth.tmc.edu, phone: 713-486-2867, or **Jair C. Soares, M.D., Professor**

and Chair, e-mail: Jair.C.Soaresh@uth.tmc.edu, phone: 713-486-2507. The University of Texas Health Science Center at Houston is an EO/AA employer. M/F/D/V.

UNIVERSITY OF CALIFORNIA, LOS ANGELES POSTDOCTORAL FELLOW

A position for Postdoctoral Research Fellow is available at the UCLA Addictions Laboratory (PI: Lara Ray). Our laboratory examines the clinical neuroscience of alcoholism, including studies of alcoholism etiology and treatment. Our focus is on translating basic science of addiction to clinically meaningful insights and interventions for clinical populations. Research methods employed include behavioral pharmacology, experimental psychopathology, neuroimaging, and clinical trials. Postdoctoral fellows will be actively involved in data analysis, manuscript preparation, and development of independent extramural grant applications. Research qualifications include a PhD or MD degree in clinical psychology, psychiatry, neuroscience, or a related field. Preferred qualifications include significant experience with substance use research and sophistication in data analytic methods. Mentoring and professional development will be provided by Dr. Lara Ray and affiliated UCLA faculty members. Opportunities for teaching and mentoring of graduate and undergraduate students is available. Opportunities for clinical practice and licensure in clinical psychology are also available. UCLA is an Equal Opportunity Employer. Lab Website: <https://addictions.psych.ucla.edu/>

UNIVERSITY OF CALIFORNIA, LOS ANGELES POSTDOCTORAL FELLOW

The UCLA Integrated Substance Abuse Programs (ISAP) invites applicants for a fulltime post-doctoral position in a thriving research organization with decades of experience conducting clinical research on substance use disorders (SUDs). This position is available for an individual interested in interdisciplinary research on SUD topics, emphasizing experimental clinical trials to develop and test effective treatments for SUDs, with a focus on opioid use disorder. Opportunities in the rich research environment based at UCLA include:

- numerous clinical trials on SUD treatment conducted by ISAP researchers and affiliated investigators at UCLA and across the nation;
- ISAP team involvement as prominent participants in the NIDA Clinical Trials Network;
- ongoing research focus on opioid use disorder (OUD), including studies on medication treatment for OUD and innovative delivery of OUD treatment;
- a focus on blending clinical practice and research, providing a rich setting in which to increase expertise in designing, conducting, and documenting clinical trials, as well as to learn skills in advanced methodologies applicable to clinical trials research.

Candidates should have a background in psychology, medicine, or neuroscience and be interested in developing expertise in clinical trials research involving pharmacotherapies and behavioral therapies for SUDs. Also

of interest are candidates with expertise in implementation science and in statistical analysis that may be applied to clinical research on SUDs. Candidates must have:

- doctoral degree in psychology, medicine, public health, or social sciences;
- excellent writing and communication skills;
- ability to work in a fast-paced, collaborative research environment;
- ability to travel to clinical sites and interact with participants and clinical personnel.

Duration of the fellowship is flexible, initially for one year, with possible extension. Salary will be commensurate with experience and demonstrated capabilities in relevant areas, including writing for scholarly publications, familiarity with good research practices, and an understanding of ethical research and protection of human research participants.

Please send a cover letter, CV, and contact information for three references to:

Yih-Ing Hser, Ph.D. (yhser@mednet.ucla.edu)
Larissa Mooney, M.D. (lmooney@mednet.ucla.edu)

VIRGINIA TECH, FRALIN BIOMEDICAL RESEARCH INSTITUTE POSTDOCTORAL ASSOCIATE

Imagine working in a stimulating environment where you will be a part of cutting-edge research discoveries where

- multiple NIH grants fund a variety of diverse interdisciplinary and translational research projects
- invaluable grant-writing experience is gained and encouraged
- you will work closely with some of the leading researchers in addiction and behavioral economics
- you are encouraged to pitch your own ideas for meaningful research projects that fall within the scope of the lab
- postdoctoral associates average 5 published manuscripts per year

Imagine a growing research institute that attracts leading scientists from across the nation -- [The Fralin Biomedical Research Institute at VTC](#) (formerly known as the Virginia Tech Carilion Research Institute) is a unique public-private partnership that leverages Virginia Tech's world-class strength in basic sciences, bioinformatics, and engineering with Carilion Clinic's highly experienced medical staff and a rich history in medical education. Virginia Tech Carilion (VTC) improves human health and quality of life by providing leadership in medical education and biomedical and clinical research. This academic health center was recently renamed Fralin Biomedical Research Institute at VTC in honor of the \$50 million donation provided by the generosity of Heywood and Cynthia Fralin to progress the growth of this institute and its contributions to medical and research advancements.

Position Summary: The [Addiction Recovery Research Center \(ARRC\)](#) is directed by Dr. Warren K. Bickel, an accomplished scholar and researcher whose work is frequently cited and receives national and international

recognition. This position will work primarily on NIH funded projects that are providing new information about substance and alcohol use disorders, health behaviors, and decision-making. Several projects are focusing on the use of the Experimental Tobacco Marketplace to investigate choice behavior among nicotine users from a behavioral economics framework. Other projects are focusing on treatments for opioid use disorder and the examination of Episodic Future Thinking to improve health in individuals with prediabetes and other lifestyle related disorders. Moreover, ARRC has ongoing projects to examine the effects of Transcranial Magnetic Stimulation on cigarette smoking and overeating. The position is well suited for individuals interested in technological and behavioral economic applications to addiction and health behavior. This postdoctoral position will also be involved in developing pilot research programs in the research areas of the lab and will be expected to help develop these additional projects.

Appointment: 1-3 yrs.

Eligibility: Candidates are expected to have a solid background in psychology, behavioral economics, and/or addiction or health behaviors research. In addition, experience with behavior analysis and/or clinical trials is highly desirable. The successful candidate will possess a PhD in psychology, neuroscience, or appropriate related discipline and have a record of research excellence as indicated by peer-reviewed publications and presentations.

Benefits: Full-time annual salary, medical insurance coverage, and travel funds supported by NIH grants. Translational research training and career development opportunities are provided as part of this position.

For more information: Contact Ms. Patsy Marshall (patsym@vtc.vt.edu).

To apply: Send cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Warren K. Bickel c/o Ms. Patsy Marshall (patsym@vtc.vt.edu). Applications will be reviewed on an ongoing basis.

About us: The Addiction Recovery Research Center (ARRC) was established in 2011 as part of the Virginia Tech Carilion Research Institute (VTCRI). The existing facilities and research teams are world-class and focus on transdisciplinary research on the scientific underpinnings of health and a range of diseases and substance use disorders. A new biomedical expansion is currently being constructed and will include additional research laboratories to focus on brain health and disorders, biomaterials-body device interfaces, cardiovascular sciences, cancer, metabolism and obesity, and infectious disease and immunity. The Fralin Biomedical Research Institute at VTC represents a new model for biomedical and behavioral science in which creative scientists can approach major problems with breadth and depth in a nurturing and intellectually challenging environment.

About Roanoke, Virginia: Roanoke, Virginia is located in Southwest Virginia in the foothills of the Appalachian Mountains and accessible by the Blue Ridge Parkway. Roanoke is a vibrant community with an active downtown full of restaurants, theaters, museums, and an amphitheater that is home to many seasonal festivals and music events. Roanoke also offers great opportunities for an active

outdoor lifestyle with 30 miles of greenway connecting charming neighborhoods and beautiful parks along the Roanoke River. Roanoke is one of two cities in the nation to earn the All-American City Award a record seven times.

GEISEL SCHOOL OF MEDICINE AT DARTMOUTH ASSISTANT PROFESSOR

The Department of Biomedical Data Science at the Geisel School of Medicine at Dartmouth (Geisel) seeks outstanding applicants for a tenure-track Assistant Professor to join our faculty within the Center for Technology and Behavioral Health (CTBH). Exceptional candidates at the rank of Associate Professor may also be considered. Dartmouth is an R1: Doctoral University – Highest Research Activity in the Carnegie Classification, and faculty members benefit from highly collaborative and collegial interactions across campus, inclusive of departments at the Geisel School of Medicine, the College of Arts & Sciences, the Thayer School of Engineering and the Tuck School of Business.

CTBH is an interdisciplinary research group whose mission is to inform the optimal development, systematic evaluation, and sustainable implementation of digital therapeutics for behavioral health and health-care delivery transformation. Successful candidates will be pursuing a vigorous research program focused on the use of novel methodologies, intervention development, data analytics and/or biostatistics in digital health. Research focused on patient/consumer engagement, clinical effectiveness, or implementation of digital health behavior-change interventions will also be considered. That may include research in adaptive digital therapeutic interventions for health behavior change; development/refinement of analytic models for intensive, longitudinal mobile health data; digital phenotyping; or biostatistical analysis of densely sampled longitudinal data. Research designed to understand mechanisms of behavior change with digital health interventions is also of interest, as are interventions focusing on addictive behaviors. The activities of the center are diverse and inter-disciplinary; hence, the call for outstanding candidates from a breadth of different disciplines spanning behavioral medicine to biostatistics.

Applicants should have a PhD, MD, or equivalent degree with relevant post-doctoral training. Formal advanced training in behavioral science, research methods, biostatistics, data science, biomedical informatics, bioinformatics or a related field is preferred. Applicants should also have a successful track record of peer-reviewed publications, and ideally a history of extramural funding. Expectations for teaching and mentoring are a critical part of this role, and individuals will be provided with such opportunities through membership in relevant PhD graduate programs (e.g., Program in Quantitative Biomedical Sciences; Program in Experimental & Molecular Medicine, The Dartmouth Institute). Training grants in relevant areas (e.g., Science of Co-occurring Disorders , BD2K Predoctoral Training in Biomedical Big Data Science,

the Burroughs Welcome training fund for Unifying Population and Laboratory-based Sciences) are available to support trainees in areas relevant to successful candidates.

Link to apply: <https://apply.interfolio.com/60277>

Contact for questions: Alan J. Budney, Ph.D.

<mailto:alan.j.budney@dartmouth.edu>

Geisel School of Medicine at Dartmouth
Center for Technology and Behavioral Health
46 Centerra Pkwy, Suite 315, HB 7255
Lebanon, NH 03766

UNIVERSITY OF FLORIDA POSTDOCTORAL FELLOW

The Translational Science Training to Reduce the Impact of Alcohol on HIV infection is seeking a postdoctoral fellow. This is a multidisciplinary NIAAA T32 training program focused on alcohol and HIV Behavioral and clinical interventions, Data science, Neurocognition, and Brain Science. Postdocs will work on NIH-Funded grants, participate in seminars and training programs, and develop their own lines of research.

The state of Florida currently ranks second in new HIV infections per year, and second in total HIV/AIDS cases in the US. Alcohol consumption contributes to poor HIV outcomes and to ongoing HIV transmission, and the relationships between alcohol consumption and HIV can vary by age, gender, ethnicity, and sexual orientation, all of which is explored as part of this program of research.

The training program supports four pre-doctoral and two post-doctoral trainees at any time. Applications are accepted on a rolling basis based on availability of positions. Pre-doctoral trainees will be based in the following academic programs: Epidemiology, Biostatistics, Clinical and Health Psychology, Nursing Science, Health Education and Behavior, and the Interdisciplinary Program in Medicine. Funding includes an annual stipend, research/travel expenses and health insurance. Individuals from under represented populations are strongly encouraged to apply. The T32 program ensures appropriate depth in knowledge regarding alcohol, HIV, and several additional focus areas that represent areas of strength in ongoing research at UF:

- Behavioral Intervention
- Cognitive Science
- Data Science
- Epidemiology
- Microbiome
- Mhealth

If you have any questions or would like to apply, please email your CV to sharct32@phhp.ufl.edu

Division 28 Executive Committee

Elected Officers

- President: Ryan Vandrey
- Past President: Kelly Dunn
- President-Elect: Tom Gould
- Council Representative: William Stoops
- Members-at-Large: Eric Donny, Dustin Stairs, Cassie Gipson-Reichardt

Appointed Officers

- Secretary: Matt Kirkpatrick
- Treasurer: Will Aklin
- Newsletter Editor: Meredith Berry
- Divisional Awards: Richard Yi
- Membership: Brent Kaplan
- Fellows: Micky Koffarnus
- Program Chair (2021: Cecilia Bergeria)
- Program Chair (2022: Jacob Borodovsky)
- Finance Committee Chair: Andrew Huhn

Early Career Appointed Liaisons/Monitors

- Student Representative: Neo Gebru, Kathleen McNealy, Andrea Vasquez Ferreiro (social media chair)

- Early Career Psychologist Representative: Justin Strickland, Kirsten Smith
- Archivist: Justin Strickland

Appointed Liaisons/Monitors

- Board of Educational Affairs: M. Marlyne Kilbey
- Electronic Information: Ronald Wood
- Liaison to Committee on Animal Research and Ethics: Mark Smith
- Liaison to Division 55: M. Marlyne Kilbey
- Women's Network Representative: Mary Cain
- Continuing Education Committee Chair: M. Marilyne Kilbey
- International Affairs Committee: Hendree Jones
- Liaison to Division 50: Linda Sobell
- Liaison to Science Directorate: Rick Bevins
- Liaison to the Board for the Advancement of Psychology in the Public Interest: Martin Iguchi